Contents lists available at ScienceDirect





General Hospital Psychiatry

journal homepage: www.elsevier.com/locate/genhospsych

Suicidal ideation and suicidal self-directed violence following clinicianinitiated prescription opioid discontinuation among long-term opioid users



Michael I. Demidenko^a, Steven K. Dobscha^{a,b}, Benjamin J. Morasco^{a,b}, Thomas H.A. Meath^{a,c}, Mark A. Ilgen^{d,e}, Travis I. Lovejov^{a,b,f,*}

^a VA Center to Improve Veteran Involvement in Care, VA Portland Health Care System, 3710 SW U.S. Veterans Hospital Road, Mail Code: R & D 66, Portland, OR 97239, United States

^b Department of Psychiatry, Oregon Health & Science University, 3181 SW U.S. Sam Jackson Park Road, Portland, OR 97239, United States

^c Center for Health Systems Effectiveness, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mail Code: MDYCHSE, Portland, Oregon 97239, United States

^d VA Center for Clinical Management Research, 2215 Fuller Road, VA Ann Arbor Health Care System, Ann Arbor, MI 48109, United States

^e Department of Psychiatry, University of Michigan, SPC 5763 2700, 4250 Plymouth Road, Ann Arbor, MI 48109, United States

^f School of Public Health, Oregon Health & Science University, 3181 SW U.S. Sam Jackson Park Road, Mail Code: CB 669, Portland, OR 97239, United States

ARTICLE INFO

Keywords: Opioid Chronic opioid therapy Opioid discontinuation Suicide Suicidal ideation Suicidal self-directed violence

ABSTRACT

Objective: Little is known about patient outcomes following discontinuation of opioid therapy, which may include suicidal ideation (SI) and suicidal self-directed violence (SSV). The purpose of this study was to examine correlates of SI and non-fatal SSV in a sample of patients discontinued from long-term opioid therapy (LTOT). *Method:* Five hundred-nine Veterans Health Administration (VHA) patients whose clinicians discontinued them from LTOT were selected from a national cohort of VHA patients who discontinued opioids in 2012. The sample comprised patients with a substance use disorder and matched controls. Patient electronic health records were manually reviewed to identify discontinuation reasons and the presence of SI or SSV in the 12 months following discontinuation.

Results: Forty-seven patients (9.2%) had SI only, while 12 patients (2.4%) had SSV. In covariate-adjusted logistic regression models, mental health diagnoses associated with having SI/SSV included post-traumatic stress disorder (aOR = 2.56, 95% CI = 1.23-5.32) and psychotic disorders (aOR = 3.19, 95% CI = 1.14-8.89). Other medical comorbidities, substance use disorder and pain diagnoses, opioid dose, and benzodiazepine prescriptions were unrelated to SI/SSV.

Conclusions: Among patients with a substance use disorder and matched controls, there are high rates of SI/SSV following opioid discontinuation, suggesting that these "high risk" patients may require close monitoring and risk prevention.

1. Introduction

Opioids are commonly prescribed to treat chronic pain [1–2]. Estimates of the prevalence of receipt of prescription opioid therapy among U.S. patients with chronic pain are as high as 20% [3]. However, recent clinical guidelines, including the 2016 CDC guidelines for prescribing opioids for chronic pain [4], discourage use of opioids as a primary analgesic therapy. Guidelines further recommend that clinicians weigh the benefits and risks of opioid therapy for each patient and discontinue opioid therapy when risks outweigh benefits. In addition, recent data from the Veterans Health Administration (VHA) indicate that the overall rate of high-dose opioid prescribing is

decreasing and that the rate of decrease may have accelerated with the implementation of national strategies designed to reduce risky opioid prescribing [5]. These trends suggest that a sizeable proportion of patients in the U.S. prescribed long-term opioid therapy may have their opioid doses lowered and, in some cases, discontinue opioid therapy in the coming years.

While some patients may discontinue opioid therapy of their own volition, data suggest that the majority of opioid discontinuations are initiated by opioid-prescribing clinicians, due to patient high-risk behaviors such as use of other illicit or prescribed controlled sub-stances, opioid misuse, opioid diversion, poor-adherence to the treatment plan, or other patient safety concerns [6]. Despite the heightened

E-mail address: travis.lovejoy@va.gov (T.I. Lovejoy).

http://dx.doi.org/10.1016/j.genhosppsych.2017.04.011

^{*} Corresponding author at: Center to Improve Veteran Involvement in Care, VA Portland Health Care System, 3710 SW U.S. Veterans Hospital Road, Mail Code: R & D 66, Portland, OR 97239, United States.

Received 3 March 2017; Received in revised form 24 April 2017; Accepted 25 April 2017 0163-8343/ Published by Elsevier Inc.

Patients prescribed opioid therapy for all of 2011, excluding opioid replacement therapy (methadone maintenance, buprenorphine) = 325,802





Fig. 1. Sample selection for patients who discontinue opioid therapy.Veterans Health Administration (VHA) patients prescribed opioid therapy for all of 2011 and who subsequently discontinued opioid therapy for at least 12 months beginning in 2012 comprised the study cohort. From this cohort, 300 patients with substance use disorder diagnoses were randomly selected and 300 patients without substance use disorder diagnoses were matched to the substance use disorder sample in order to conduct comprehensive chart review. A total of 509 patients were discontinued from opioid therapy by a clinician and comprise the analytic sample.

risk these patients may face for opioid-related adverse events, some clinicians have expressed concerns about discontinuing opioid therapy for patients they deem to be unstable or who may possess fewer pain coping resources and pain self-management skills [7]. Of particular concern to clinicians is the possibility that discontinuing opioid therapy may cause or exacerbate suicidal ideation in some patients [8]. Concerns about suicide risk are warranted given that those with chronic pain are at elevated risk for suicide and this risk is even greater in those receiving higher opioid doses [9–10]. However, the extent to which opioid discontinuation is associated with suicide risk has not been examined previously.

The primary objective of this study was to identify predictors of suicidal ideation (SI) and non-fatal suicidal self-directed violence (SSV) following clinician-initiated discontinuation of long-term opioid therapy. A secondary objective was to examine incidence and correlates of SI and SSV among patients who did not have SI or SSV prior to opioid discontinuation.

2. Methods

This study was approved by the U.S. Department of Veterans Affairs Portland Health Care System Institutional Review Board.

2.1. Sample selection

Data were extracted from the VHA Corporate Data Warehouse (CDW) to identify a national cohort of all VHA patients prescribed long-term opioid therapy, which we defined as continuous opioid therapy for all of 2011. The CDW is a national data repository that provides comprehensive information contained in VHA patients' electronic medical records. Similar to prior studies [11–12], our definition of continuous opioid therapy allowed prescription refill gaps of no > 30 days between completion of an opioid prescription and refill of the next opioid prescription to account for delayed prescription refills resulting from travel, prescription mail order delays, and other circumstances. The mean number of days prescribed opioids in 2011 for this cohort was 351 of 365 days (standard deviation = 17 days).

From this cohort, we identified patients who discontinued prescription opioid therapy—i.e., had no VHA opioid prescriptions—for at least 12 consecutive months starting some time in 2012. We chose a 12month discontinuation interval to ensure discontinuation was an intended treatment decision and not due to factors that may delay prescription refills of active opioid prescriptions such as geographic relocation, switching care to another VHA facility, and extended inpatient hospitalizations. The date of the last opioid refill was used as an index date for each patient to ascertain patient sociodemographic and clinical characteristics prior to discontinuation. Because this study focuses on patients with chronic non-cancer pain, we excluded patients with the following characteristics in the year prior to the index date: (1) the only opioid therapy prescribed was through a VHA opioid substitution program (i.e., buprenorphine or methadone maintenance therapy), (2) a diagnosis of cancer, (3) enrollment in hospice or long-term care, or (4) having received surgery for which opioids may have been prescribed. We also excluded patients with no VHA contact (i.e., no VHA clinical encounters or medications prescribed) or who died in the year following discontinuation, as well as non-veterans or veteran patients whose only medical care was obtained at a facility located in a U.S. territory.

From the cohort of 7247 patients who discontinued opioid therapy in 2012, we selected 600 patients in order to ascertain detailed information about reasons for discontinuation of opioid therapy and post-discontinuation incidence of SI and SSV based on comprehensive electronic health record review. Consistent with the U.S. Centers for Disease Control and Prevention's classification system for self-directed violence, we defined SSV as "behavior that is self-directed and deliberately results in injury or the potential for injury to oneself" and "there is evidence, whether implicit or explicit, of suicidal intent" (p. 21) [13]. Data for the current study were derived from a research project where the goal was to examine differences in reasons for discontinuation of opioid therapy between patients with and without substance use disorders. The sample thus comprised 300 patients with a substance use disorder diagnosis (randomly selected from 1868 patients with a substance use disorder diagnosis) and 300 propensity scorematched patients without a substance use disorder diagnosis (selected from the 5379 patients without a substance use disorder diagnosis) in the year prior to the index date. Details about the matching procedures have been described elsewhere [6]. Fig. 1 details sample selection and the number of patients meeting each exclusion criterion.

2.2. Data sources and study variables

2.2.1. Electronic health record review

A trained research associate experienced with reviewing and coding VHA medical charts for opioid-related studies performed all electronic health record reviews. Additional details about the training and quality assurance procedures have been described elsewhere [6]. Review of patients' electronic health records identified patient and clinician reasons for discontinuation of opioid therapy. Patients could be coded as having multiple patient- or clinician-initiated discontinuation reasons (e.g., a patient may have had an aberrant urine toxicology screen and been suspected of diverting opioid medication). However, all reasons for discontinuation for each patient were classified as either patient-initiated or clinician-initiated in this sample. Of the 600 patients who discontinued opioid therapy, 509 discontinuations (85%) were initiated by clinicians; these 509 patients comprise the study's analytic sample.

Clinician-initiated discontinuation reasons included (1) "Aberrant Behaviors", comprising aberrant urine drug tests, suspected use of alcohol or other substances, opioid misuse, opioid diversion, and non-adherence to plan of care (e.g., failing to present for a urine drug test when asked); (2) "Patient Safety Concerns", comprising prior opioid overdose, high risk for an opioid-related adverse event, and contra-indication with other prescribed medication such as benzodiazepines; (3) "Lack of Efficacy", comprising opioids not indicated for type of chronic pain, opioids not decreasing pain, and opioids not improving functioning; (4) opioids now prescribed by a non-VHA prescriber; (5) no reason documented in the electronic medical record; and (6) other reason. These discontinuation reasons have been described in greater detail elsewhere [6].

For the current study, chart review also identified documentation in patients' electronic health records of SI and non-fatal SSV in the year following opioid discontinuation. SI and SSV were ascertained by reviewing all VHA inpatient and outpatient clinical notes (including primary and specialty medical and mental health care) in the specified time frame. By definition, any patient with SSV was also considered to have SI. A secondary aim of this study was to identify whether the SI and SSV within this sample were new or pre-existing. As such, for patients with documentation of SI or SSV post-opioid discontinuation, we expanded our review of the electronic health record for these patients to determine if SI or SSV had also been documented in the record in the 12 months prior to discontinuation of opioid therapy. We did not review electronic health records for pre-discontinuation SI or SSV in patients who did not have electronic health record documentation of SI or SSV post-discontinuation.

2.2.2. Administrative data

Data were abstracted from the CDW for the 12 months prior to opioid discontinuation. We obtained demographic characteristics (age, gender, race/ethnicity) and rurality of patients' place of residence based on rural-urban commuting area codes [14]. Medical comorbidities were assessed with the Elixhauser Comorbidity Index [15], where higher scores indicate a greater number of comorbidities. VHA Service Connected Disability status, which is disability granted to veteran patients as a result of military service-related injuries or traumas, was also obtained. Diagnoses of mental health disorders, substance use disorders, chronic pain syndromes, and sleep disorders were obtained for the year prior to discontinuation. Opioid-related variables assessed over the year prior to discontinuation included average daily dose of opioids in morphine equivalents (a metric used to standardize opioid dose across different opioid medications), and number of opioid prescribers in the year prior to discontinuation. We also identified patients who were prescribed benzodiazepines in the year prior to discontinuation.

2.3. Statistical analyses

We utilized chi-square tests of association for categorical variables and independent sample t-tests for continuous variables to compare sociodemographic, medical comorbidity, and clinical care variables between patients with and without SI/SSV. We next conducted multivariate logistic regression to examine the covariate-adjusted associations of these variables with SI/SSV. Sample size limitations precluded identification of variables associated with SSV alone, due to the low number of documented cases of SSV in this sample. In Step 1 of the model, we included sociodemographic variables found to be associated with SI/SSV in prior studies: age, gender, and race/ethnicity [16-18]. In Step 2, we added to the model measures of medical comorbidity, disability status, and clinical diagnoses previously found to be associated with SI/SSV [16-18]. Step 2 variables included the Elixhauser Comorbidity Index, any VHA Service Connected Disability (yes vs. no), and diagnoses given in the 12 months prior to opioid discontinuation of depressive disorder, bipolar disorder, post-traumatic stress disorder (PTSD), other anxiety disorders, psychotic disorders (e.g., schizophrenia), any alcohol or other substance use disorder (excluding tobacco use disorder), tobacco use disorder, chronic pain diagnoses (i.e., musculoskeletal pain, neuropathic pain, and migraine headache), and sleep disorder. Finally, in Step 3, we added to the model clinical care variables that may increase patients' risk of SI/SSV. These included benzodiazepine prescriptions, opioid dose in the year prior to opioid discontinuation (measured in average daily morphine equivalents), and opioid discontinuation reasons that may place patients at increased risk for adverse events, namely, opioid-related aberrant behaviors and patient safety concerns. To examine correlates of new onset SI/SSV, we repeated the 3-step multivariate logistic regression described above, excluding patients with SI/SSV in the year after discontinuation of opioid therapy who also had documented SI/SSV in the medical record in the year prior to discontinuation (n = 25). All inferential analyses used two-sided tests of significance and alpha = 0.05.

Table 1

Demographic and clinical characteristics based on presence of suicidal ideation or non-fatal suicidal self-directed violence in the 12 months following discontinuation of long-term opioid therapy.

%n) or M ± SD%n) or M ± SD%n) or M ± SDSocied <th>Variable</th> <th>Full sample N = 509</th> <th>SI/SSV n = 59</th> <th>No SI/SSV n = 450</th> <th>p-Value</th>	Variable	Full sample N = 509	SI/SSV n = 59	No SI/SSV n = 450	p-Value
		%(n) or M \pm SD	%(n) or M \pm SD	%(n) or M \pm SD	
Age 55.0 ± 10.4 52.5 ± 9.6 55.3 ± 10.4 0.05 Male gender 94.3% (480) 94.9% (56) 94.2% (424) 0.83 Race/ethnicity 0.01 0.01 0.01 0.01 Mike, non-Hispanic 16.9% (56) 1.9% (7) 1.2% (79) 1.3% (79) Hispanic 16.9% (56) 8.5% (5) 1.3% (70) 1.2% (52) 6.8% (4) 1.5% (50)	Sociodemographic characteristics				
Male gender943% (480)943% (560)942% (52)96.3%Nace/thnity70.7% (560)72.9% (43)70.4% (37)90.3%Bick, non-Hispanic6.9% (56)1.9% (7)7.6% (79)1.7% (79)Hispanic2.3% (11)8.5% (5)1.3% (6)0.7% (80)Other/unknown12.2% (52)6.9% (50)4.4% (20)7.2%Isolated12.2% (52)11.9% (7)4.4% (23)7.2%Jandard12.2% (52)11.9% (7)2.2% (53)7.2%Large rund6.4% (23)5.5% (53)6.4% (33)7.2%Unknown0.4% (23)7.6% (34)7.2%7.2%Unknown1.6 ± 1.41.7 ± 1.31.6 ± 1.47.2%Any VHA Service Connected Disability5.6% (24)5.5% (24)7.2%Depressive Gonoret Disability5.4% (23)7.6% (34)2.3%Depressive Gonder Ginagenee2.3% (12)3.5% (18)2.3% (10)0.24Johar disorder2.5% (12)0.5% (18)2.5% (13)0.30Other anxievy disorder2.5% (14)1.5% (13)1.5% (13)0.3%Pyschotic Ginagenee2.5% (14)5.1% (33)0.240.32Opiclar disorder2.5% (14)5.1% (33)0.4% (3)0.24Arboti use disorder7.5% (14)5.1% (33)0.4% (3)0.24Opiclar disorder2.5% (14)5.1% (33)0.4% (3)0.24Opiclar disorder2.5% (14)5.1% (33)0.4% (3)0.24Opiclar disorder2.5% (14)5.1%	Age	55.0 ± 10.4	52.5 ± 9.6	55.3 ± 10.4	0.05
Race-Charlicity Out Out Out Out Out Out White, non-Hispanic 16.9% (86) 11.9% (7) 17.6% (79) 13.8% (6) 13.8% (5) 13.8% (6) Under, non-Hispanic 10.2% (52) 6.8% (4) 10.7% (48) 7.8% (2) 13.8% (5)	Male gender	94.3% (480)	94.9% (56)	94.2% (424)	0.83
White, non-Itispanic70.% (360)72.9% (43)70.4% (317)Black, non-Itispanic22% (11)8.5% (5)1.3% (6)Other, vinknown10.2% (52)8.5% (5)1.3% (6)Rural-urban continuum12.2% (12)8.5% (5)4.4% (20)Small rural12.2% (62)11.9% (7)12.2% (53)Lipsanic8.4% (43)8.5% (5)8.4% (33)Urban0.4% (20)0.0% (0)0.4% (2)Urban0.4% (20)0.0% (0)0.4% (2)Urban dignoses and medical comorbidities11.7 ± 1.31.6 ± 1.4Bipolar disorder1.6 ± 1.40.59 (13)0.72Any VHA Service Connected Disability5.4% (282)7.5% (13)0.24Bipolar disorder2.4% (12)0.5% (18)2.4% (11)0.32Pisto disorder3.0% (15)4.1% (23)0.02Pisto disorder2.5% (12)1.5% (3)0.02Other anxiety disorder2.5% (12)1.5% (3)0.02Other anxiety disorder2.5% (13)1.6% (3) </td <td>Race/ethnicity</td> <td></td> <td></td> <td></td> <td>0.01</td>	Race/ethnicity				0.01
Black, non-Hispanic16,9% (86)11,9% (7)17,6% (79)Hispanic10.2% (52)6.5% (5)1.3% (6)Nurban continuum10.2% (52)6.5% (5)4.4% (20)Isolated12.2% (62)11.9% (7)12.2% (53)Large rural12.2% (62)11.9% (7)12.2% (53)Large rural12.2% (62)71.2% (42)74.4% (38)Urban74.1% (37)71.2% (42)74.4% (38)Urban16.4 1.41.7 ± 1.31.6 ± 1.40.59Unknown16.5 ± 1.47.7 ± 1.31.6 ± 1.40.59Any VIA Scruce Connected Disability55.4% (22)57.6% (24)5.1% (24)0.25Persetice Gonderd Disability56.4% (22)35.6% (18)2.6% (106)0.25Popersetice Gonderd Disability56.4% (22)35.6% (18)2.6% (106)0.25PirSD30.6% (150)41.1% (26)2.8% (130)0.25Optica marker disorder5.3% (12)0.5% (18)2.4% (11)0.33Subtarne us disorder diagnoses7.5% (140)5.1% (33)6.0% (27)0.76Andohu us disorder7.5% (140)5.1% (33)6.0% (27)0.76Cocaine us disorder7.5% (140)5.1% (33)6.0% (23)0.25Optica us disorder5.5% (23)5.8% (27)4.2% (19)0.25Optica us disorder5.5% (23)5.6% (25)0.6%0.6%Cocaine us disorder5.5% (23)5.6% (25)0.6%0.6%Optica us disorder diagnosi5.5% (23)5.6% (25)0	White, non-Hispanic	70.7% (360)	72.9% (43)	70.4% (317)	
Highnic22% (11)8.5% (5)1.3% (6)Other/unkowa0.2% (52)0.5% (5)0.7% (48)Furni-tran continum12.2% (52)1.19% (7)1.2.2% (53)Small rural8.4% (43)8.5% (5)8.4% (38)Urban2.4% (62)0.0% (0)0.4% (33)Urban0.4% (2)0.0% (0)0.4% (2)Urban0.4% (2)0.0% (0)0.4% (2)Urban0.4% (2)0.0% (0)0.4% (2)Urban0.4% (2)0.0% (0)0.4% (2)Urban0.4% (2)0.0% (0)0.4% (2)Urban comorbidity lafe:1.6 ± 1.41.7 ± 1.31.6 ± 1.4May VHA Scrice Connected Disability5.4% (282)7.6% (34)0.24Bipolar disorder2.4.4% (124)0.5% (18)2.3.6% (106)0.24Bipolar disorder2.4.4% (124)0.5% (18)2.6% (130)0.24Other ankiey disorder2.4.4% (124)0.5% (18)2.6% (130)0.24Disorder disorder3.0% (150)1.6% (13)0.26Other ankiey disorder2.5% (120)1.5% (13)0.26Other ankiey disorder2.5% (120)1.5% (13)0.26Other ankiey disorder5.9% (30)5.3% (29)0.76Amphetamine use disorder5.9% (30)5.1% (33)0.26Other ankiey disorder5.9% (30)5.1% (33)0.26Other ankiey disorder5.9% (30)5.3% (29)0.76Amphetamine use disorder5.9% (30)5.3% (30)0.26Other ankiey disorde	Black, non-Hispanic	16.9% (86)	11.9% (7)	17.6% (79)	
Other10.2% (52)63% (5)10.7% (69)0.72Ivaria-urian continum4.9% (51)8.5% (5)4.4% (20)0.72Small nural12.2% (62)11.9% (7)12.2% (55)1.1%Large runal8.4% (33)8.5% (5)0.4% (28)1.1%Urban74.9% (37)71.2% (42)74.4% (33)1.1%Urban0.4% (2)0.6% (0)0.4% (2)1.1%Clinical diagnoses and medical comorbidity1.6 ± 1.41.7 ± 1.31.6 ± 1.40.72Any VIA Service Connected Diability55.4% (22)57.6% (34)51.1% (24)0.72Perestive disorder1.4% (12)0.5% (18)2.36% (106)0.24Biplar disorder2.4% (12)30.5% (18)2.36% (106)0.24Popessive disorder2.4% (12)30.5% (18)2.36% (106)0.24Pipsbarce us disorder2.4% (12)30.5% (18)2.36% (106)0.24Pipsbarce us disorder2.5% (140)1.5% (28)0.760.76Any Na Service Connect diagnoses1.9% (17)7.5% (33)0.250.76Vistance use disorder diagnose2.5% (140)1.5% (13)1.5% (13)0.760.76Any Ha Service Connect diagnose2.5% (140)1.9% (7)0.5% (13)0.760.76Ang Las Confer2.5% (140)1.9% (7)1.5% (32)0.760.76Optica us disorder5.9% (140)1.9% (7)1.5% (140)0.760.76Any Las Confer2.5% (140)1.9% (7)1.5% (32)0.76<	Hispanic	2.2% (11)	8.5% (5)	1.3% (6)	
ImplicationUNUNUNUNIsolatedA9% (25)A.5% (5)A4% (20)ISmall rural1.2% (62)11.9% (7)1.2% (53)ILubanA4% (43)A.5% (5)A.4% (38)IUthan0.2% (20)0.2% (20)0.4% (23)IUthan0.4% (23)0.2% (20)0.4% (23)0.2% (20)Clinical diagnoses and medical comorbidity1.6 ± 1.41.7 ± 1.31.6 ± 1.40.59Any VAA Service Connected Disability0.5.4% (22)0.6% (24)0.51% (248)0.24Bipolar diagnoses1.6 ± 1.41.9% (7)7.6% (34)0.24Bipolar diagnoser0.6% (156)4.4% (150)2.6% (130)0.02Other maicy disorder0.5% (120)0.5% (18)2.6% (130)0.02Psychotic disorder0.5% (120)0.5% (18)2.6% (130)0.02Anothu us disorder2.5% (120)0.5% (18)2.6% (130)0.03Anghetamine use disorder2.5% (120)1.5% (30)0.100.10Cannabis use disorder2.5% (130)1.6% (11)1.2% (55)0.10Opticatus disorder2.5% (120)1.6% (11)1.6% (15)0.03Opticatus disorder2.6% (13)6.8% (10)2.6% (12)0.03Opticatus disorder2.6% (13)6.8% (12)0.6% (13)0.6% (13)0.6% (13)0.6% (13)Opticatus disorder3.5% (28)5.1% (30)5.6% (25)0.6%0.8%Opticatus disorder diagnosi5.1% (13)6.	Other/unknown	10.2% (52)	6.8% (4)	10.7% (48)	
Isolated4.9% (25)8.5% (5)4.4% (20)Small runal12.2% (52)11.9% (7)12.2% (52)8.4% (38)Large runal8.4% (37)71.2% (42)74.4% (335)1Uhan0.4% (2)0.0% (0)0.4% (2)1Clinical diagnoses and medical comorbidities1.6 ± 1.41.7 ± 1.31.6 ± 1.40.72Any VHA Service Connected Disbibility5.5.4% (282)57.6% (34)55.1% (248)0.72Metal lealth diagnoses2.4.4% (124)1.9% (7)7.6% (34)0.25Perservice Gontexel Disbibility6.0% (15)44.1% (26)28.9% (130)0.24Other ansiety disorder2.5.% (129)0.5% (18)2.6.% (100)0.24Other ansiety disorder2.5.% (100)0.240.720.72Pytohic disorder2.5.% (129)0.5% (18)2.6.% (130)0.24Anopheating use disorder2.5.% (120)0.5% (18)2.6.% (130)0.32Pytohic disorder2.5% (14)2.5% (15)2.7.% (13)0.23Opicid use disorder2.9% (13)0.5% (13)6.0% (27)0.78Opicid use disorder2.9% (13)0.8% (30)0.100.72Opicid use disorder2.6% (13)6.8% (13)0.8% (13)0.24Opicid use disorder2.6% (13)6.8% (27)0.780.78Opicid use disorder2.6% (13)6.8% (27)0.780.78Opicid use disorder2.6% (13)6.8% (13)0.6% (13)0.80Opicid use disorder2.6% (13) <td< td=""><td>Rural-urban continuum</td><td></td><td></td><td></td><td>0.72</td></td<>	Rural-urban continuum				0.72
Small runal12,2% (2)11,9% (7)12,2% (5)Large runal8,4% (43)8,5% (5)8,4% (43)1.4% (335)Urhan van74,1% (377)71,2% (42)74,4% (335)Urhan van74,1% (377)71,2% (42)74,4% (335)Urhan van74,1% (377)71,2% (42)74,4% (335)Urhan van1.6 ± 1.41.7 ± 1.31.6 ± 1.4.6 ± 1.4Stabuser Comorbidity Index1.6 ± 1.41.7 ± 1.31.6 ± 1.4.6 ± 1.4Mary VHA Service Connected Disability65,4% (282)57.6% (34)2.36% (106).024Bipolar disorder24.4% (124)30.5% (18)23.6% (106).025PTSD30.6% (156)41.1% (26)28.9% (130).022Other ansiety disorder30.6% (156)41.1% (26)28.9% (130).023Psychotic disorder2.5% (140)15.3% (9).71% (32).033Substance use disorder2.5% (101)5.1% (33)1.8% (8).010Granalis use disorder2.5% (130)5.1% (33).6% (25).058Cocaine use disorder2.6% (13)6.8% (4)2.0% (9).033Optici use disorder2.6% (13)6.8% (27)4.2% (199).82Optic use disorder5.1% (33)5.6% (25).056Tobacco use disorder diagnosis4.4% (26)45.8% (27)4.2% (199).82Pind diagnoses10.2% (6)10.2% (6).6% (25).056Tobacco use disorder diagnosis5.1% (33)5.6% (25).056Muscu disorder </td <td>Isolated</td> <td>4.9% (25)</td> <td>8.5% (5)</td> <td>4.4% (20)</td> <td></td>	Isolated	4.9% (25)	8.5% (5)	4.4% (20)	
Large rural8.4% (3)8.5% (5)8.4% (38)Urban74.1% (377)7.2% (42)74.4% (335)Urbanown0.4% (23)0.4% (23)0.4% (23)Clinical diagnoses and medical comorbidities11.5 ± 1.31.6 ± 1.40.59Any VHA Service Connected bisbility55.4% (282)57.6% (34)55.1% (248)0.72Mental1.6 ± 1.41.5 ± 1.6 ± 1.40.590.6%More and the diagnoses30.5% (181)2.36% (106)0.24Depressive disorder0.4% (124)30.5% (181)2.36% (106)0.24Bipolar disorder0.6% (156)1.4% (156)2.8.9% (130)0.02Other anxiety disorder0.6% (156)1.4% (156)2.4.7% (111)0.33PyrsD30.6% (156)3.5% (181)2.4.7% (111)0.33PyrsD30.6% (156)1.5% (31)1.5% (33)0.70Auble at disorder2.5% (140)5.1% (33)6.0%0.70Auble at disorder2.5% (131)5.1% (33)0.6%0.70Coarine use disorder2.5% (131)5.1% (33)0.4%0.76Opioi due disorder2.6% (131)1.1% (57)0.780.76Sectaire use disorder2.6% (131)1.2% (55)0.16Opioi due disorder3.2% (67)1.8% (81)0.190.76Sectaire use disorder3.2% (67)1.8% (81)0.190.76Sectaire use disorder6.1% (131)1.2% (56)0.160.16Opioi due disorder6.1% (131)1.2% (56)<	Small rural	12.2% (62)	11.9% (7)	12.2% (55)	
Urban 74.1% (377) 71.2% (42) 74.4% (335) Unknown 0.4% (2) 0.6% (0) 0.4% (2) Clinical diagnoses and medical comorbidities 1 1.7 ± 1.3 1.6 ± 1.4 0.59 Any VHA Service Connected Disability 1.6 ± 1.4 1.7 ± 1.3 1.6 ± 1.4 0.59 Any VHA Service Connected Disability 1.6 ± 1.4 1.7 ± 1.3 1.6 ± 1.4 0.59 Mental health diagnoses 1.8 (4) (24) 30.5% (18) 2.36% (106) 0.24 Bipolar disorder 2.4% (124) 30.5% (18) 2.8.9% (130) 0.602 Other anxiety disorder 2.5% (129) 0.5% (18) 2.4.9% (111) 0.33 Pyschotic diagnoses 1 1.5.3% (9) 7.1% (22) 0.03 Subtance use disorder 2.5% (140) 5.4% (15) 7.1% (25) 0.76 Amphetamine use disorder 2.9% (101) 1.5.4% (3) 0.24 Goaine use disorder 2.9% (130) 0.10 0.3 0.24 Goaine use disorder 2.9% (101) 1.8.9% (8) 0.10 0.3	Large rural	8.4% (43)	8.5% (5)	8.4% (38)	
Unknown 0.4% (2) 0.0% (0) 0.4% (2) Clinical diagnoses and medical contribities - - - Elikabuse Controbitoly Index 1.6 ± 1.4 1.7 ± 1.3 1.6 ± 1.4 0.59 Any VHA Service Connected Disability 5.4% (282) 57.6% (34) 55.1% (248) 0.72 Mental health diagnoses - - - - 0.72 Depressive disorder 24.4% (124) 30.5% (18) 23.6% (106) 0.24 Bipolar disorder 30.6% (156) 44.1% (26) 28.9% (130) 0.30 Other anxiety disorder 2.5% (129) 30.5% (18) 24.7% (111) 0.33 Substance use disorder diagnoses -	Urban	74.1% (377)	71.2% (42)	74.4% (335)	
Clinical diagnoses and medical comorbidities Elinka user Comorbidity Index 1.6 ± 1.4 1.7 ± 1.3 1.6 ± 1.4 0.59 Any VHA Service Connected Disability 55.4% (282) 57.6% (34) 55.1% (248) 0.27 Mental health diagnoses 0.29 0.21 0.25 Bipolar disorder 8.1% (41) 1.9% (7) 7.6% (34) 0.25 PTSD 30.6% (156) 4.1% (26) 28.9% (130) 0.02 Other anxiety disorder 8.1% (41) 15.3% (9) 7.1% (32) 0.03 Psychotic disorder 8.1% (41) 15.3% (9) 7.1% (32) 0.03 Subtance use disorder diagnoses 7.5% (140) 5.1% (33) 6.0% (7) 0.76 Anophetamine use disorder 2.5% (10) 5.1% (33) 6.0% (7) 0.72 0.00 0.03 Cocanie use disorder 2.9% (40) 1.19% (7) 7.3% (33) 0.22 0.00 Sedative use disorder 3.2% (67) 8.6% (13) 6.0% (2) 0.6% Other substance use disorder 6.1%	Unknown	0.4% (2)	0.0% (0)	0.4% (2)	
Elixhauser comorbidity Index1.6 ± 1.41.7 ± 1.31.6 ± 1.40.59Any VHA Service Connected Disability55.4% (282)57.6% (34)55.1% (248)0.72Mental health diagnoses <td>Clinical diagnoses and medical comorbidities</td> <td></td> <td></td> <td></td> <td></td>	Clinical diagnoses and medical comorbidities				
Any VHA Service Connected Disability 55.4% (282) 57.6% (34) 55.1% (248) 0.72 Mental health diagnoses	Elixhauser Comorbidity Index	1.6 + 1.4	1.7 ± 1.3	1.6 + 1.4	0.59
Mental health diagnoses Number of the second s	Any VHA Service Connected Disability	55.4% (282)	57.6% (34)	55.1% (248)	0.72
Depressive disorder 24.4% (124) 30.5% (18) 23.6% (106) 0.24 Bipolar disorder 8.1% (41) 11.9% (7) 7.6% (34) 0.25 PTSD 30.6% (156) 41.4% (26) 28.9% (130) 0.02 Other anxiety disorder 25.3% (129) 30.5% (18) 24.7% (111) 0.33 Psychotic disorder 8.1% (41) 5.1% (32) 25.3% (129) 0.5% (18) 24.7% (111) 0.33 Substance use disorder diagnoses 7.5% (140) 25.4% (15) 27.8% (125) 0.70 Amphetamine use disorder 2.9% (30) 5.1% (3) 6.0% (27) 0.78 Cocaine use disorder 7.9% (40) 11.9% (7) 7.3% (33) 0.22 Opioid use disorder 2.6% (13) 6.6% (11) 12.4% (56) 0.19 Sedative use disorder 6.0% (13) 10.2% (67) 4.8% (24) 0.90 0.03 Other substance use disorder 6.0% (13) 10.2% (65) 0.6% 0.88 1.9% 0.84 Nuculoskeletal 85.1% (433) 84.7% (50) 85.1% (383) 0.	Mental health diagnoses				
Biplar disorder 8.1% (41) 11.9% (7) 7.6% (34) 0.25 PTSD 30.6% (156) 44.1% (26) 28.9% (130) 0.02 Other anxiety disorder 25.3% (129) 30.5% (18) 24.7% (111) 0.33 Psychotic disorder 8.1% (41) 15.3% (9) 7.1% (32) 0.03 Substance use disorder diagnoses	Depressive disorder	24.4% (124)	30.5% (18)	23.6% (106)	0.24
PTSD 30.6% (156) 44.1% (26) 28.9% (130) 0.02 Other anxiety disorder 25.3% (129) 30.5% (18) 24.7% (111) 0.33 Psychotic disorder 8.1% (41) 15.3% (9) 7.1% (32) 0.03 Substance use disorder diagnoses 7.1% (32) 0.03 0.03 Anphetamine use disorder 27.5% (140) 25.4% (15) 27.8% (125) 0.70 Amphetamine use disorder 2.9% (13) 5.1% (33) 6.0% (27) 0.78 Canabis use disorder 5.9% (30) 5.1% (33) 6.0% (27) 0.78 Cocaine use disorder 7.9% (40) 11.9% (7) 7.3% (33) 0.22 Opioid use disorder 2.6% (13) 6.6% (41) 2.0% (9) 0.03 Other substance use disorder 6.1% (31) 10.2% (6) 5.6% (25) 0.16 Tobacco use disorder diagnosis 4.4% (26) 4.7% (50) 5.1% (383) 0.94 Neuropathy 5.5% (28) 5.1% (30) 5.6% (25) 0.88 Migraine headache 10.4% (53) 16.9% (10) 9.6% (43)	Bipolar disorder	8.1% (41)	11.9% (7)	7.6% (34)	0.25
Other anxiety disorder 25.3% (129) 30.5% (18) 24.7% (111) 0.33 Psychotic disorder 8.1% (41) 15.3% (9) 7.1% (32) 0.03 Substance use disorder 27.5% (140) 25.4% (15) 27.8% (125) 0.70 Amphetamine use disorder 2.2% (11) 5.1% (3) 1.8% (8) 0.10 Cannabis use disorder 5.9% (30) 5.1% (3) 6.0% (27) 0.78 Cocaine use disorder 7.9% (40) 19.9% (7) 7.3% (33) 0.22 Opioid use disorder 13.2% (67) 18.6% (11) 12.4% (56) 0.19 Sedative use disorder 2.6% (13) 6.8% (4) 2.0% (9) 0.63 Other substance use disorder 6.1% (31) 10.2% (6) 5.6% (25) 0.16 Tobacco use disorder diagnosis 44.4% (226) 45.8% (27) 44.2% (199) 0.82 Pain diagnoses I I I 9.6% (3) 0.94 Musculoskeletal 85.1% (433) 8.47% (50) 85.1% (33) 0.94 Sleep disorder diagnosis 7.5% (28) 5	PTSD	30.6% (156)	44.1% (26)	28.9% (130)	0.02
Psychotic disorder 8.1% (4) 15.3% (9) 7.1% (32) 0.03 Substance use disorder diagnoses 27.5% (140) 25.4% (15) 27.8% (125) 0.70 Anophetamine use disorder 2.2% (11) 5.1% (3) 1.8% (8) 0.10 Cannabis use disorder 2.2% (11) 5.1% (3) 6.0% (27) 0.78 Cocaine use disorder 7.9% (40) 11.9% (7) 7.3% (33) 0.22 Opioid use disorder 3.2% (67) 8.6% (11) 12.4% (56) 0.19 Sedative use disorder 2.6% (13) 6.8% (4) 2.0% (9) 0.03 Other substance use disorder 6.1% (31) 10.2% (6) 5.6% (25) 0.6 Tobacco use disorder diagnosis 44.4% (26) 45.8% (27) 44.2% (199) 0.3 Pain diagnoses 11.9% (7) 5.5% (28) 5.1% (33) 6.9% (25) 8.8 Musculoskeletal 85.1% (433) 84.7% (50) 85.1% (33) 0.94 Sleep disorder diagnosis 7.5% (38) 6.8% (4) 7.6% (34) 0.83 Sleep disorder diagnosis 7.5% (38) 6.8% (4) 7.6% (34) 0.83 Clinical care 7.5% (38) 88.6 ± 93.7 74.0 ± 89.0 0.24 Number of opioid prescribers 2.6 ± 1.6 2.9 ± 1.7 2.5 ± 1.6 0.11 Reason for discontinuation of opioid therapy 7.5% (382) 81.4% (48) 74.2% (334) 0.23 Patient safety concerns 7.5% (382) 81.4% (48) 6.4% (29) 0.5	Other anxiety disorder	25.3% (129)	30.5% (18)	24.7% (111)	0.33
Substance use disorder diagnoses 27.5% (140) 25.4% (15) 27.8% (125) 0.70 Amphetamine use disorder 2.2% (11) 5.1% (3) 1.8% (8) 0.10 Cannabis use disorder 2.2% (11) 5.1% (3) 6.0% (27) 0.78 Cocaine use disorder 7.9% (40) 11.9% (7) 7.3% (33) 0.22 Opioid use disorder 13.2% (67) 18.6% (11) 12.4% (56) 0.19 Sedative use disorder 6.6% (13) 6.8% (4) 2.0% (9) 0.03 Other substance use disorder 6.1% (31) 10.2% (6) 5.6% (25) 0.82 Pain diagnoses	Psychotic disorder	8.1% (41)	15.3% (9)	7.1% (32)	0.03
Alcohol use disorder 27.5% (140) 25.4% (15) 27.8% (125) 0.70 Amphetamine use disorder 2.2% (11) 5.1% (3) 1.8% (8) 0.10 Gannabis use disorder 5.9% (30) 5.1% (3) 6.0% (27) 0.78 Gocaine use disorder 7.9% (40) 11.9% (7) 7.3% (33) 0.22 Opioid use disorder 13.2% (67) 18.6% (11) 12.4% (56) 0.19 Sedative use disorder 6.6% (4) 2.0% (9) 0.03 Other substance use disorder 6.1% (31) 10.2% (6) 5.6% (25) 0.16 Tobacco use disorder diagnosis 44.4% (226) 45.8% (27) 44.2% (199) 0.82 Pain diagnoses - <td>Substance use disorder diagnoses</td> <td></td> <td></td> <td></td> <td></td>	Substance use disorder diagnoses				
Amphetamine use disorder 2.2% (11) 5.1% (3) 1.8% (8) 0.10 Cannabis use disorder 5.9% (30) 5.1% (3) 6.0% (27) 0.78 Cocaine use disorder 7.9% (40) 11.9% (7) 7.3% (33) 0.22 Opioid use disorder 13.2% (67) 8.6% (11) 1.4% (56) 0.19 Sedative use disorder 2.6% (13) 6.8% (41) 2.0% (9) 0.03 Other substance use disorder 6.1% (31) 10.2% (6) 5.6% (25) 0.16 Tobacco use disorder diagnosis 44.4% (226) 8.5% (27) 8.51% (383) 0.94 Pain diagnoses 0.96 0.88 Musculoskeletal 85.1% (433) 84.7% (50) 85.1% (383) 0.94 Neuropathy 5.5% (28) 5.1% (3) 5.6% (25) 0.88 Migraine headache 0.4% (53) 6.8% (4) 0.6% (3) 0.83 Sleep disorder diagnosis 7.5% (38) 6.8% (4) 7.6% (34) 0.24 Quinber of opioid prescribers 2.6 ± 1.6 2.9 ± 1.7 </td <td>Alcohol use disorder</td> <td>27.5% (140)</td> <td>25.4% (15)</td> <td>27.8% (125)</td> <td>0.70</td>	Alcohol use disorder	27.5% (140)	25.4% (15)	27.8% (125)	0.70
Canabis use disorder 5.9% (30) 5.1% (3) 6.0% (27) 0.78 Cocaine use disorder 7.9% (40) 11.9% (7) 7.3% (33) 0.22 Opioid use disorder 13.2% (67) 18.6% (11) 12.4% (56) 0.19 Sedative use disorder 2.6% (13) 6.8% (41) 2.0% (9) 0.03 Other substance use disorder 6.1% (31) 10.2% (6) 5.6% (25) 0.16 Tobacco use disorder diagnosis 44.4% (226) 45.8% (27) 44.2% (199) 0.82 Pain diagnoses 5.6% (25) 0.68 Musculoskeletal 85.1% (433) 84.7% (50) 5.6% (25) 0.88 Musculoskeletal 10.4% (53) 16.9% (10) 9.6% (43) 0.88 Sleep disorder diagnosis 7.5% (38) 6.8% (4) 7.6% (34) 0.83 Sleep disorder diagnosis 13.0% (66) 11.9% (7) 13.1% (59) 0.79 Average MEDD 75.7 ± 89.6 86.6 ± 93.7 74.0 ± 89.0 0.24 Number of opioid prescribers 2.9 ± 1.7 2.9 ± 1.6 0	Amphetamine use disorder	2.2% (11)	5.1% (3)	1.8% (8)	0.10
Cocaine use disorder 7.9% (40) 11.9% (7) 7.3% (33) 0.22 Opioid use disorder 13.2% (67) 18.6% (11) 12.4% (56) 0.19 Sedative use disorder 2.6% (13) 6.8% (4) 2.0% (9) 0.03 Other substance use disorder 6.1% (31) 10.2% (6) 5.6% (25) 0.16 Tobacco use disorder diagnosis 4.4% (26) 45.8% (27) 44.2% (19) 0.82 Pain diagnoses 5.5% (28) 5.1% (33) 0.94 Neuropathy 5.5% (28) 5.1% (33) 5.6% (25) 0.88 Migraine headache 10.4% (53) 16.9% (10) 9.6% (43) 0.08 Sleep disorder diagnosis 7.5% (38) 6.8% (4) 7.6% (34) 0.83 Clinical care 7.5.7 ± 89.6 88.6 ± 93.7 74.0 ± 89.0 0.24 Number of opioid prescribers 2.6 ± 1.6 2.9 ± 1.7 2.5 ± 1.6 0.11 Reason for discontinuation of opioid therapy 7.5% (382) 81.4% (48) 74.2% (334) 0.23 <	Cannabis use disorder	5.9% (30)	5.1% (3)	6.0% (27)	0.78
Opioid use disorder 13.2% (67) 18.6% (11) 12.4% (56) 0.19 Sedative use disorder 2.6% (13) 6.8% (4) 2.0% (9) 0.03 Other substance use disorder 6.1% (31) 10.2% (6) 5.6% (25) 0.16 Tobacco use disorder diagnosis 4.4% (226) 45.8% (27) 4.2% (199) 0.23 Pain diagnoses	Cocaine use disorder	7.9% (40)	11.9% (7)	7.3% (33)	0.22
Sedative use disorder 2.6% (13) 6.8% (4) 2.0% (9) 0.03 Other substance use disorder 6.1% (31) 10.2% (6) 5.6% (25) 0.16 Tobacco use disorder diagnosis 44.4% (226) 45.8% (27) 44.2% (199) 0.82 Pain diagnoses	Opioid use disorder	13.2% (67)	18.6% (11)	12.4% (56)	0.19
Other substance use disorder 6.1% (31) 10.2%(6) 5.6% (25) 0.16 Tobacco use disorder diagnosis 44.4% (226) 45.8% (27) 44.2% (199) 0.82 Pain diagnoses 0.44 Musculoskeletal 85.1% (433) 84.7% (50) 85.1% (383) 0.94 Neuropathy 5.5% (28) 5.1% (30) 5.6% (25) 0.88 Migraine headache 10.4% (53) 16.9% (10) 9.6% (43) 0.88 Sleep disorder diagnosis 7.5% (38) 6.8% (4) 7.6% (34) 0.89 Clinical care 13.0% (66) 11.9% (7) 13.1% (59) 0.79 Average MEDD 75.7 ± 89.6 88.6 ± 93.7 74.0 ± 89.0 0.24 Number of opioid prescribers 2.6 ± 1.6 2.9 ± 1.7 2.5 ± 1.6 0.11 Reason for discontinuation of opioid therapy 75.0% (382) 81.4% (48) 74.2% (334) 0.23 Patient safety concerns 75.3% (37) 13.6% (8) 6.4% (29) 0.05	Sedative use disorder	2.6% (13)	6.8% (4)	2.0% (9)	0.03
Tobacco use disorder diagnosis 44.4% (226) 45.8% (27) 44.2% (199) 0.82 Pain diagnoses $uusculoskeletal85.1\% (433)84.7\% (50)85.1\% (383)0.94Neuropathy5.5\% (28)5.1\% (33)5.6\% (25)0.88Migraine headache10.4\% (53)16.9\% (10)9.6\% (43)0.08Sleep disorder diagnosis7.5\% (38)6.8\% (4)7.6\% (34)0.79Clinical careuusculoskeletal13.0\% (66)11.9\% (7)13.1\% (59)0.79Prescribed benzodiazepine13.0\% (66)11.9\% (7)2.5 \pm 1.60.11Reason for discontinuation of opioid therapy2.6 \pm 1.62.9 \pm 1.72.5 \pm 1.60.11Reason for discontinuation of opioid therapy75.0\% (382)81.4\% (48)74.2\% (334)0.23Patient safety concerns7.3\% (37)13.6\% (8)6.4\% (29)0.05$	Other substance use disorder	6.1% (31)	10.2%(6)	5.6% (25)	0.16
Pain diagnoses Musculoskeletal 85.1% (433) 84.7% (50) 85.1% (383) 0.94 Neuropathy 5.5% (28) 5.1% (3) 5.6% (25) 0.88 Migraine headache 10.4% (53) 16.9% (10) 9.6% (43) 0.08 Sleep disorder diagnosis 7.5% (38) 6.8% (4) 7.6% (34) 0.83 Clinical care 7.5% (56) 11.9% (7) 13.1% (59) 0.79 Average MEDD 75.7 ± 89.6 88.6 ± 93.7 74.0 ± 89.0 0.24 Number of opioid prescribers 2.6 ± 1.6 2.9 ± 1.7 2.5 ± 1.6 0.11 Reason for discontinuation of opioid therapy 45.0% (382) 81.4% (48) 74.2% (334) 0.23 Patient safety concerns 7.3% (37) 13.6% (8) 6.4% (29) 0.05	Tobacco use disorder diagnosis	44.4% (226)	45.8% (27)	44.2% (199)	0.82
Musculoskeletal 85.1% (433) 84.7% (50) 85.1% (383) 0.94 Neuropathy 5.5% (28) 5.1% (3) 5.6% (25) 0.88 Migraine headache 10.4% (53) 16.9% (10) 9.6% (43) 0.08 Sleep disorder diagnosis 7.5% (38) 6.8% (4) 7.6% (34) 0.83 Clinical care 7.5% (36) 11.9% (7) 13.1% (59) 0.79 Average MEDD 75.7 ± 89.6 88.6 ± 93.7 74.0 ± 89.0 0.24 Number of opioid prescribers 2.6 ± 1.6 2.9 ± 1.7 2.5 ± 1.6 0.11 Reason for discontinuation of opioid therapy 75.0% (382) 81.4% (48) 74.2% (334) 0.23 Patient safety concerns 73.% (37) 13.6% (8) 6.4% (29) 0.05	Pain diagnoses				
Neuropathy 5.5% (28) 5.1% (3) 5.6% (25) 0.88 Migraine headache 10.4% (53) 16.9% (10) 9.6% (43) 0.08 Sleep disorder diagnosis 7.5% (38) 6.8% (4) 7.6% (34) 0.83 Clinical care 7.5% (36) 11.9% (7) 13.1% (59) 0.79 Average MEDD 75.7 ± 89.6 88.6 ± 93.7 74.0 ± 89.0 0.24 Number of opioid prescribers 2.6 ± 1.6 2.9 ± 1.7 5.1% (334) 0.23 Reason for discontinuation of opioid therapy 75.0% (382) 81.4% (48) 74.2% (334) 0.23 Patient safety concerns 75.0% (382) 81.4% (48) 64% (29) 0.05	Musculoskeletal	85.1% (433)	84.7% (50)	85.1% (383)	0.94
Migraine headache 10.4% (53) 16.9% (10) 9.6% (43) 0.08 Sleep disorder diagnosis 7.5% (38) 6.8% (4) 7.6% (34) 0.83 Clinical care 7.5% (36) 11.9% (7) 13.1% (59) 0.79 Prescribed benzodiazepine 13.0% (66) 11.9% (7) 13.1% (59) 0.24 Number of opioid prescribers 26 ± 1.6 29 ± 1.7 2.5 ± 1.6 0.24 Reason for discontinuation of opioid therapy 45.0% (382) 81.4% (48) 74.2% (334) 0.23 Patient safety concerns 75.0% (382) 81.4% (48) 6.4% (29) 0.05	Neuropathy	5.5% (28)	5.1% (3)	5.6% (25)	0.88
Sleep disorder diagnosis 7.5% (38) 6.8% (4) 7.6% (34) 0.83 Clinical care	Migraine headache	10.4% (53)	16.9% (10)	9.6% (43)	0.08
Clinical care I1.9% (7) 13.1% (59) 0.79 Prescribed benzodiazepine 13.0% (66) 11.9% (7) 13.1% (59) 0.24 Average MEDD 75.7 ± 89.6 88.6 ± 93.7 74.0 ± 89.0 0.24 Number of opioid prescribers 2.6 ± 1.6 2.9 ± 1.7 2.5 ± 1.6 0.11 Reason for discontinuation of opioid therapy Jaherrant behaviors 75.0% (382) 81.4% (48) 74.2% (334) 0.23 Patient safety concerns 7.3% (37) 13.6% (8) 6.4% (29) 0.05	Sleep disorder diagnosis	7.5% (38)	6.8% (4)	7.6% (34)	0.83
Prescribed benzodiazepine 13.0% (66) 11.9% (7) 13.1% (59) 0.79 Average MEDD 75.7 ± 89.6 88.6 ± 93.7 74.0 ± 89.0 0.24 Number of opioid prescribers 2.6 ± 1.6 2.9 ± 1.7 2.5 ± 1.6 0.11 Reason for discontinuation of opioid therapy 0.23 Aberrant behaviors 75.0% (382) 81.4% (48) 74.2% (334) 0.23 Patient safety concerns 7.3% (37) 13.6% (8) 6.4% (29) 0.05	Clinical care				
Average MEDD 75.7 ± 89.6 88.6 ± 93.7 74.0 ± 89.0 0.24 Number of opioid prescribers 2.6 ± 1.6 2.9 ± 1.7 2.5 ± 1.6 0.11 Reason for discontinuation of opioid therapy	Prescribed benzodiazepine	13.0% (66)	11.9% (7)	13.1% (59)	0.79
Number of opioid prescribers 2.6 ± 1.6 2.9 ± 1.7 2.5 ± 1.6 0.11 Reason for discontinuation of opioid therapy 75.0% (382) 81.4% (48) 74.2% (334) 0.23 Patient safety concerns 7.3% (37) 13.6% (8) 6.4% (29) 0.05	Average MEDD	75.7 ± 89.6	88.6 ± 93.7	74.0 ± 89.0	0.24
Reason for discontinuation of opioid therapy State State<	Number of opioid prescribers	2.6 ± 1.6	2.9 ± 1.7	2.5 ± 1.6	0.11
Aberrant behaviors 75.0% (382) 81.4% (48) 74.2% (334) 0.23 Patient safety concerns 7.3% (37) 13.6% (8) 6.4% (29) 0.05	Reason for discontinuation of opioid therapy				
Patient safety concerns 7.3% (37) 13.6% (8) 6.4% (29) 0.05	Aberrant behaviors	75.0% (382)	81.4% (48)	74.2% (334)	0.23
	Patient safety concerns	7.3% (37)	13.6% (8)	6.4% (29)	0.05

Demographic characteristics, clinical diagnoses, medical comorbidities, and prescription information were obtained for the year prior to discontinuation of opioid therapy.

MEDD = Morphine Equivalent Daily Dose, PTSD = Post-Traumatic Stress Disorder, SI = Suicidal Ideation, SSV = Non-fatal Suicidal Self-directed Violence, VHA = Veterans Health Administration.

Items in bold are significant at $p \leq 0.05$.

3. Results

This study sample comprised 509 patients prescribed long-term opioid therapy for chronic pain, predominantly musculoskeletal pain (85%), whose clinicians discontinued patients' prescriptions for opioid therapy. Similar to the population of veterans prescribed opioid therapy through VHA [12,19], the study sample had a mean age of 55 years, was predominantly male (94%), non-Hispanic white (71%), and resided in urban locations (74%). Sixty-one percent of patients in this sample received a diagnosis for at least one mental health disorder in the year prior to discontinuation of opioid therapy, including PTSD (31%), anxiety disorders other than PTSD (25%), depressive disorders (24%), bipolar affective disorders (8%), and psychotic disorders (8%). Per study design, approximately half of patients were diagnosed with at least one substance use disorder in the year prior to discontinuation; the most common diagnoses were alcohol use disorder (28%), opioid use disorder (13%), and cocaine use disorder (8%). The majority of patients (75%) were discontinued from opioid therapy due to aberrant behaviors. Table 1 provides characteristics of the full sample and the subsamples of patients with and without SI/SSV.

Approximately 12% of patients in this sample (n = 59) had SSV and/or SI documented in the VHA medical record in the 12 months following discontinuation of opioid therapy. Forty-seven had SI only, while 12 had SSV. Of the 12 patients with documented SSV, 6 patients attempted to overdose on prescription medication (4 of the 6 on benzodiazepines), 1 attempted to overdose using amphetamines and cocaine, 3 patients cut their wrists, 1 patient attempted to hang himself, and another attempted to take his life using a firearm but someone intervened before he could complete the act. Of the 59 patients with documented SI/SSV in the 12 months following discontinuation of opioid therapy, 34 had no documentation in the medical record of SI/SSV in the year prior to discontinuation, and thus met our definition of new onset SI/SSV.

Table 2

Multivariate correlates of any suicidal ideation or non-fatal suicidal self-directed violence in the year following discontinuation of long-term opioid therapy.

Demographic characteristics Jes O.97 (0.95-1.00) 0.98 (0.95-1.01) 0.97 (0.95-1.00) Age Male gender 1.36 (0.39-4.81) 1.39 (0.39-5.01) 1.39 (0.37-5.10) Har Reference Reference Reference Reference Reference Black, non-Hispanic 0.67 (0.29-1.56) 0.72 (0.30-1.72) 0.76 (0.31-1.83) Other/unknown 0.62 (0.21-1.82) 7.94 (2.15-29.28) 7.25 (1.96-27.18) Other/unknown 0.62 (0.21-1.82) 0.66 (0.22-0.00) 0.65 (0.21-0.12) Clinical diagnoses and medical comorbiditis - 0.87 (0.65-1.16) 0.87 (0.65-1.16) May VHA Service Connected Disability - 0.73 (0.38-1.40) 0.71 (0.37-1.37) Mental health diagnose - 1.31 (0.68-2.50) 1.29 (0.67-2.49) Bioplar disorder - 1.32 (0.60-3.55) 1.49 (0.53-6.7) Propresive disorder disgnosis - 1.32 (0.60-3.50) 1.49 (0.53-6.7) Other anxicty disorders - 3.34 (1.23-9.11) 3.19 (1.14-8.89) Subtance use disorder diagnosis - 1.00 (0.06-1.89) 0.82 (0.36-1		Model 1	Model 2	Model 3
Åge render0.97 (0.95-1.00)0.98 (0.95-1.01)0.97 (0.95-1.01)Male gender1.36 (0.39-4.01)1.39 (0.39-5.01)1.39 (0.37-5.01)RaceReferenceReferenceReferenceBlack, non-HispanicReforenceReferenceReferenceReferenceBlack, non-Hispanic0.62 (0.21-1.82)7.94 (2.15-29.28)7.25 (1.96-27.18)Other/unknown0.62 (0.21-1.82)0.66 (0.22-2.00)0.65 (0.21-2.01)Clinical diagnoses0.87 (0.65-1.16)0.87 (0.65-1.16)0.87 (0.65-1.16)Any HA Service Connected Disability-0.87 (0.65-1.16)0.87 (0.65-1.16)Appender-0.31 (0.68-2.50)0.71 (0.37-1.37)Mental-0.33 (1.04-4.78)0.29 (0.67-2.49)Bipolar disorder-1.31 (0.68-2.50)1.29 (0.67-2.49)PTSD1.31 (0.68-2.50)1.29 (0.67-2.49)Poptical Giorder-1.31 (0.68-2.50)1.29 (0.67-2.49)Bipolar disorder1.39 (0.63-1.80)0.80 (0.53-1.80)PTSD1.31 (0.68-2.50)1.29 (0.67-2.49)Poptical Eiser disorder diagnosisNutstance disorder diagnosisOther anxiety disordersNutstance disorder diagnosisNutstance disorder diagnosisNutstance disorder diagnosisNutstance disorder diagnosis-	Demographic characteristics			
Male gender1.36 (0.39-4.81)1.39 (0.39-5.01)1.39 (0.37-5.21)RacWhite, non-HispanicReferenceReferenceReferenceReferenceReferenceBlack, non-Hispanic0.67 (0.29-1.56)0.72 (0.30-1.72)0.75 (0.13-1.83)0.75 (0.13-1.83)Hispanic0.64 (0.88-2.2.35)7.94 (2.15-2.9.28)7.26 (1.96-7.18)Other/unknown0.62 (0.21-1.82)0.66 (0.22-0.00)0.65 (0.21-2.01)Clinical diagnoses and medical comorbiditiesElixhauser Medical Comorbidity Index-0.87 (0.65-1.16)0.87 (0.65-1.16)Any 'HA Service Connected Disability-0.87 (0.65-1.36)0.97 (0.37-1.37)Mettar1.31 (0.68-2.50)1.29 (0.67-2.49)Bipolar disorder-1.31 (0.68-2.50)1.29 (0.67-2.49)Popresvie disorder1.32 (0.60-3.85)1.40 (0.53-3.67)PTSD0.83 (0.14-4.78)0.92 (0.46-1.82)Substance use disorder diagnosis-0.98 (0.50-1.89)0.92 (0.46-1.82)Substance use disorder diagnosis-0.98 (0.50-1.89)0.98 (0.53-1.80)Chronic pain diagnose0.02 (0.62-3.81)0.92 (0.46-3.82)Mustudekelat pain0.66 (0.20-2.18)0.93 (0.24-3.61)Mustudekelat pain0.65 (0.20-2.18)0.93 (0.24-3.61)Neuropathic pain0.67 (0.20-2.18)0.72 (0.22-2.38)Neuropathic pain0.67 (0.20-2.18)0.72 (0.22-2.38) <td>Age</td> <td>0.97 (0.95-1.00)*</td> <td>0.98 (0.95-1.01)</td> <td>0.97 (0.95-1.00)</td>	Age	0.97 (0.95-1.00)*	0.98 (0.95-1.01)	0.97 (0.95-1.00)
RaceVerticeReferenceRef	Male gender	1.36 (0.39-4.81)	1.39 (0.39-5.01)	1.39 (0.37-5.21)
Mether, non-HispanicReferenceReferenceReferenceBack, non-Hispanic0.67 (0.29-1.56)0.72 (0.30-1.72)0.76 (0.31-83)Hispanic6.48 (1.88-22.35)7.94 (2.15-29.28)0.25 (0.62-2.18)Other/unknown0.62 (0.21-1.82)0.66 (0.22-2.00)0.65 (0.21-2.01)Clinical diagnoses and medical comorbiditiesElixhauser Medical Comorbidity Index-0.87 (0.65-1.16)0.87 (0.65-1.16)Any VHA Service Connected Disability-0.73 (0.38-1.40)0.71 (0.37-1.37)Mettar-0.73 (0.38-1.40)1.29 (0.67-2.49)Biploar disorder1.52 (0.60-3.85)1.40 (0.53-3.67)Poressive disorder-1.52 (0.60-3.85)1.40 (0.53-3.67)PTSD3.33 (1.14-478)2.56 (1.33-5.32)Other anxiety disorders-0.98 (0.50-1.89)0.98 (0.53-1.80)Tobacco use disorder diagnosis-3.34 (1.23-9.11)3.19 (1.14-8.89)Subtance use disorder diagnosis-3.34 (1.23-9.11)3.19 (1.14-8.89)Tobacco use disorder diagnosis-0.99 (0.57-1.69)0.98 (0.53-1.80)Tobacco use disorder diagnosis-1.60 (0.60-1.89)0.98 (0.53-1.80)Neuropatine pain-0.99 (0.27-3.69)0.93 (0.24-3.61)Neuropatine pain-0.99 (0.27-3.69)0.93 (0.24-3.61)Neuropatine pain-0.99 (0.27-3.69)0.92 (0.22-3.89)Neuropatine pain-0.66 (0.26-1.80)0.72 (0.22-3.89)Neuropatine pai	Race			
Black, non-Hispanic 0.67 (0.29–1.56) 0.72 (0.30–1.72) 0.76 (0.31–1.83) Hispanic 648 (1.88–22.35) 7.94 (2.15–29.28) 7.25 (1.96–27.18) Other/unknown 0.66 (0.22–00) 0.65 (0.21–0.18) Clinical diagnoses and medical comorbidities	White, non-Hispanic	Reference	Reference	Reference
Hispanic 6.48 (1.88–22.35)* 7.94 (2.15–29.28)* 7.25 (1.96–27.18)* Other/unknown 0.62 (0.21–1.82) 0.66 (0.22–0.00) 0.65 (0.21–0.10) Clinical diagnoses - 0.87 (0.65–1.16) 0.87 (0.65–1.16) Any VHA Service Connected Disability - 0.73 (0.38–1.40) 0.71 (0.37–1.37) Metat - 0.73 (0.38–1.40) 0.71 (0.37–1.37) Depresive disorder - 0.73 (0.38–1.40) 0.29 (0.67–2.49) Bipolar disorder - 1.31 (0.68–2.50) 1.40 (0.53–3.67) Portservice disorder disonder - - 2.33 (1.14–4.78) 2.56 (1.23–5.32) Other ankiety disorders - 0.98 (0.50–1.89) 0.92 (0.64–1.82) Prychotic-spectrum disorders - 0.98 (0.50–1.89) 0.92 (0.64–1.82) Subtance use disorder diagnosis - 0.99 (0.60–1.98) 0.92 (0.64–1.82) Chronic pain diagnoses - 0.99 (0.70–1.98) 0.92 (0.56–1.89) Verbace disorder diagnosis - 0.99 (0.27–3.69) 0.93 (0.24–3.61) Muskuloskeletal pain - 0.99 (0.20–3.69)	Black, non-Hispanic	0.67 (0.29-1.56)	0.72 (0.30-1.72)	0.76 (0.31-1.83)
Other/unknown 0.62 (0.21–1.82) 0.66 (0.22–2.00) 0.65 (0.21–2.01) Clinical diagnoses and medical comorbidity Index 0.87 (0.65–1.16) 0.87 (0.65–1.16) 0.87 (0.65–1.16) 0.87 (0.65–1.16) 0.71 (0.37–1.37) <	Hispanic	6.48 (1.88-22.35)*	7.94 (2.15-29.28)*	7.25 (1.96-27.18)*
Clinical diagnoses and medical comorbidities 0.87 (0.65-1.16) 0.87 (0.65-1.16) Flickhauser Medical Comorbidity Index - 0.73 (0.38-1.40) 0.71 (0.37-1.37) Anny VHA Service Connected Disability - 0.73 (0.38-1.40) 0.71 (0.37-1.37) Mental health diagnoses - 1.31 (0.68-2.50) 1.29 (0.67-2.49) Bipolar disorder - 1.52 (0.60-3.85) 1.40 (0.53-3.67) PTSD - 2.33 (1.14-4.78) 2.56 (1.23-5.32) Other anxiety disorders - 0.98 (0.50-1.89) 0.92 (0.46-1.82) PytSD - 3.34 (1.23-9.11) 3.19 (1.14-8.89) Substance use disorder diagnosis - 1.06 (0.58-1.92) 1.02 (0.56-1.82) Tobacco use disorder diagnosis - 1.06 (0.58-1.92) 1.02 (0.56-1.82) Chronic pain diagnoses - 1.06 (0.58-1.92) 1.02 (0.56-1.82) Muskuloskeletal pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Neuropathic pain - 0.66 (0.26-1.81) 0.66 (0.26-1.81) Migraine headache - 1.14 (0.48-2.68) 1.17 (0.49-2.81) Slee pidsorder diagnosis - 0.66 (0.26-1.81)	Other/unknown	0.62 (0.21–1.82)	0.66 (0.22–2.00)	0.65 (0.21-2.01)
Elixhauser Medical Comorbidity Index - 0.87 (0.65-1.16) 0.87 (0.65-1.16) Any VHA Service Connected Disability - 0.73 (0.38-1.40) 0.71 (0.37-1.37) Mental health diagnoses - 1.31 (0.68-2.50) 1.29 (0.67-2.49) Bipolar disorder - 1.52 (0.60-3.85) 1.40 (0.53-3.67) PTSD - 0.98 (0.50-1.89) 0.92 (0.46-1.82) Other anxiety disorders - 0.98 (0.50-1.89) 0.92 (0.46-1.82) PrSD - 0.98 (0.50-1.89) 0.92 (0.46-1.82) Substance use disorder diagnosis - 0.98 (0.50-1.89) 0.92 (0.46-1.82) Substance use disorder diagnosis - 0.98 (0.50-1.89) 0.98 (0.53-1.80) Tobacco use disorder diagnosis - 1.06 (0.58-1.92) 0.98 (0.53-1.80) Chronic pain diagnose - 0.88 (0.39-2.00) 0.82 (0.36-1.90) Neuropathic pain - 0.88 (0.39-2.00) 0.82 (0.36-1.90) Neuropathic pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Migraine headache - 0.67 (0.20-2.18) 0.93 (0.24-3.61)	Clinical diagnoses and medical comorbidities			
Any WA Service Connected Disability - 0.73 (0.38-1.40) 0.71 (0.37-1.37) Mental health diagnoses -	Elixhauser Medical Comorbidity Index	-	0.87 (0.65-1.16)	0.87 (0.65-1.16)
Mental health diagnoses - 1.31 (0.68-2.50) 1.29 (0.57-2.49) Bipolar disorder - 1.52 (0.60-3.85) 1.40 (0.53-3.67) PTSD - 2.33 (1.14-4.78) 2.56 (1.23-5.32) Other anxiety disorders - 0.98 (0.50-1.89) 0.92 (0.46-1.82) Psychotic-spectrum disorders - 0.98 (0.50-1.89) 0.92 (0.46-1.82) Substance use disorder diagnosis - 0.98 (0.50-1.89) 0.98 (0.53-1.80) Tobacco use disorder diagnosis - 1.09 (0.60-1.98) 0.98 (0.53-1.80) Chronic pain diagnoses - 1.06 (0.58-1.92) 1.02 (0.56-1.88) Muskuloskeletal pain - 0.88 (0.39-2.00) 0.82 (0.36-1.90) Neuropathic pain - 0.88 (0.39-2.00) 0.93 (0.24-3.61) Neuropathic pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Neuropathic pain - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Sleep disorder diagnosis - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Clinical care - - 0.68 (0.26-1.81) Average MEDD in the year prior to discontinuation - - 0.68 (0.26-1.81)	Any VHA Service Connected Disability	-	0.73 (0.38-1.40)	0.71 (0.37-1.37)
Depressive disorder - 1.31 (0.68-2.50) 1.29 (0.67-2.49) Bipolar disorder - 1.52 (0.60-3.85) 1.40 (0.53-3.67) PTSD - 2.33 (1.14-4.78) 2.56 (1.23-5.32) Other anxiety disorders - 0.98 (0.50-1.89) 0.92 (0.64-1.82) Psychotic-spectrum disorders - 3.34 (1.23-9.11) 3.19 (1.14-8.39) Substance use disorder diagnosis - 1.09 (0.60-1.98) 0.98 (0.53-1.80) Tobacco use disorder diagnosis - 1.09 (0.60-1.98) 0.98 (0.53-1.80) Obacco use disorder diagnosis - 1.09 (0.60-1.98) 0.98 (0.53-1.80) Muskuloskeletal pain - 0.88 (0.39-2.00) 0.82 (0.36-1.90) Neuropathic pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Migraine headache - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Clinical care - 0.68 (0.26-1.81) 0.72 (0.22-2.38) Clinical care - 0.68 (0.26-1.81) 0.01 (0.10.10) Reason for discontinuation - 0.68 (0.26-1.81) 0.01 (0.10.10) Reaso	Mental health diagnoses			
Bipolar disorder - 1.52 (0.60-3.85) 1.40 (0.53-3.67) PTSD - 2.33 (1.14-78) 2.56 (1.23-5.32) Other anxiety disorders - 0.98 (0.50-1.89) 0.92 (0.42-1.82) Psychotic-spectrum disorders - 3.34 (1.23-9.11) 3.19 (1.14-8.89) Substance use disorder diagnosis - 1.09 (0.60-1.98) 0.98 (0.53-1.80) Tobacco use disorder diagnosis - 1.06 (0.58-1.92) 1.02 (0.56-1.88) Chronic pain diagnoses - 1.06 (0.58-1.92) 0.98 (0.30-1.80) Muskuloskeletal pain - 0.88 (0.39-2.00) 0.82 (0.36-1.90) Muskuloskeletal pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Migraine headache - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Migraine headache - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Clinical care - - 0.68 (0.26-1.81) Prescribed benzodiazepine in the year prior to discontinuation - - 0.68 (0.26-1.81) Average MEDD in the year prior to discontinuation - - 0.06 (0.26-1.81) Reason for discontinuation of opioid therapy - -	Depressive disorder	-	1.31 (0.68-2.50)	1.29 (0.67-2.49)
PTSD - 2.33 (1.14-4.78) 2.56 (1.23-5.32) Other anxiety disorders - 0.98 (0.50-1.89) 0.92 (0.46-1.82) Psychotic-spectrum disorders - 3.34 (1.23-9.11) 3.19 (1.14-8.89) Substance use disorder diagnosis - 0.09 (0.50-1.98) 0.98 (0.53-1.80) Tobacco use disorder diagnosis - 0.60 (0.58-1.92) 0.102 (0.56-1.88) Chronic pain diagnoses - 0.60 (0.58-1.92) 0.20 (0.56-1.88) Muskuloskeletal pain - 0.88 (0.39-2.00) 0.82 (0.36-1.90) Neuropathic pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Migraine headache - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Sleep disorder diagnosis - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Clinical care - - 0.68 (0.26-1.81) Reason for discontinuation - - 0.68 (0.26-1.81) Average MEDD in the year prior to discontinuation - - 0.60 (0.20-2.18) Reason for discontinuation of opioid therapy - - 0.60 (0.20-1.81) Reason for discontinuation of opioid therapy - - 0.60 (0.	Bipolar disorder	-	1.52 (0.60-3.85)	1.40 (0.53–3.67)
Other anxiety disorders - 0.98 (0.50-1.89) 0.92 (0.46-1.82) Psychotic-spectrum disorders - 3.34 (1.23-9.11) 3.19 (1.14-8.89) Substance use disorder diagnosis - 1.09 (0.60-1.98) 0.98 (0.53-1.80) Tobacco use disorder diagnosis - 0.66 (0.58-1.92) 0.82 (0.35-1.80) Tobacco use disorder diagnosis - 0.60 (0.58-1.92) 0.92 (0.46-1.82) Tobacco use disorder diagnosis - 0.60 (0.58-1.92) 0.92 (0.50-1.88) Chronic pain diagnoses - - 0.88 (0.39-2.00) 0.82 (0.36-1.90) Neuropathic pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) 0.93 (0.24-3.61) Migraine headache - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Sleep disorder diagnosis - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Clinical care - - 0.68 (0.26-1.81) Average MEDD in the year prior to discontinuation - - 0.60 (1.00-1.01) Reason for discontinuation of opioid therapy - - - 0.61 (0.76-3.42) Patient safety concerns <td>PTSD</td> <td>-</td> <td>2.33 (1.14-4.78)*</td> <td>2.56 (1.23-5.32)*</td>	PTSD	-	2.33 (1.14-4.78)*	2.56 (1.23-5.32)*
Psychotic-spectrum disorders - 3.34 (1.23-9.11) 3.19 (1.14-8.89) Substance use disorder diagnosis - 1.09 (0.60-1.98) 0.98 (0.53-1.80) Tobacco use disorder diagnosis - 1.06 (0.58-1.92) 0.98 (0.53-1.80) Tobacco use disorder diagnosis - 1.06 (0.58-1.92) 0.92 (0.56-1.88) Chronic pain diagnoses - - - - Muskuloskeletal pain - 0.88 (0.39-2.00) 0.82 (0.36-1.90) Neuropathic pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Migraine headache - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Sleep disorder diagnosis - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Clinical care - - 0.68 (0.26-1.81) Average MEDD in the year prior to discontinuation - - 0.68 (0.26-1.81) Average MEDD in the year prior to discontinuation - - 0.68 (0.26-1.81) Reason for discontinuation of opioid therapy - - - Aberrant behaviors - - 1.61 (0.76-3.42)	Other anxiety disorders	-	0.98 (0.50-1.89)	0.92 (0.46-1.82)
Substance use disorder diagnosis - 1.09 (0.60-1.98) 0.98 (0.53-1.80) Tobacco use disorder diagnosis - 1.06 (0.58-1.92) 1.02 (0.56-1.88) Chronic pain diagnoses - 0.88 (0.39-2.00) 0.82 (0.36-1.90) Muskuloskeletal pain - 0.88 (0.39-2.00) 0.93 (0.24-3.61) Neuropathic pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Migraine headache - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Sleep disorder diagnosis - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Clinical care - - 0.68 (0.26-1.81) Prescribed benzodiazepine in the year prior to discontinuation - - 0.68 (0.26-1.81) Average MEDD in the year prior to discontinuation - - 1.00 (1.00-1.01) Reason for discontinuation of opioid therapy - - 1.61 (0.76-3.42) Patient safety concerns - - 2.06 (0.82-5.18)	Psychotic-spectrum disorders	-	3.34 (1.23-9.11)*	3.19 (1.14-8.89)*
Tobacco use disorder diagnosis - 1.06 (0.58–1.92) 1.02 (0.56–1.88) Chronic pain diagnoses - 0.88 (0.39–2.00) 0.82 (0.36–1.90) Muskuloskeletal pain - 0.99 (0.27–3.69) 0.93 (0.24–3.61) Neuropathic pain - 0.99 (0.27–3.69) 0.93 (0.24–3.61) Migraine headache - 1.14 (0.48–2.68) 1.17 (0.49–2.81) Sleep disorder diagnosis - 0.67 (0.20–2.18) 0.27 (0.22–2.38) Clinical care - - - 0.68 (0.26–1.81) Prescribed benzodiazepine in the year prior to discontinuation - - 0.68 (0.26–1.81) Average MEDD in the year prior to discontinuation - - 0.68 (0.26–1.81) Reason for discontinuation of opioid therapy - - 1.06 (0.76–3.42) Patient shehviors - - 1.61 (0.76–3.42) Patient safety concerns - - 0.06 (0.82–5.18)	Substance use disorder diagnosis	-	1.09 (0.60–1.98)	0.98 (0.53-1.80)
Chronic pain diagnoses - 0.88 (0.39-2.00) 0.82 (0.36-1.90) 0.82 (0.36-1.90) Neuropathic pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Migraine headache - 1.14 (0.48-2.68) 1.17 (0.49-2.81) Sleep disorder diagnosis - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Clinical care - - - - Prescribed benzodiazepine in the year prior to discontinuation - - 0.68 (0.26-1.81) Average MEDD in the year prior to discontinuation - - 1.00 (1.00-1.01) Reason for discontinuation of opioid therapy - - 1.01 (0.76-3.42) Patient safety concerns - - 1.61 (0.76-3.42)	Tobacco use disorder diagnosis	-	1.06 (0.58-1.92)	1.02 (0.56–1.88)
Muskuloskeletal pain - 0.88 (0.39-2.00) 0.82 (0.36-1.90) Neuropathic pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Migraine headache - 1.14 (0.48-2.68) 1.17 (0.49-2.81) Sleep disorder diagnosis - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Clinical care - - - - Prescribed benzodiazepine in the year prior to discontinuation - - - - Average MEDD in the year prior to discontinuation - - - - - - 0.60 (1.00-1.01) - </td <td>Chronic pain diagnoses</td> <td></td> <td></td> <td></td>	Chronic pain diagnoses			
Neuropathic pain - 0.99 (0.27-3.69) 0.93 (0.24-3.61) Migraine headache - 1.14 (0.48-2.68) 1.17 (0.49-2.81) Sleep disorder diagnosis - 0.67 (0.20-2.18) 0.72 (0.22-2.38) Clinical care - - - - Prescribed benzodiazepine in the year prior to discontinuation - - - - Average MEDD in the year prior to discontinuation - - 0.67 (0.20-2.18) 0.100 (1.00-1.01) Reason for discontinuation of opioid therapy - - - 0.60 (1.00-1.01) Reason for discontinuation of poioid therapy - - - - - Aberrant behaviors -	Muskuloskeletal pain	-	0.88 (0.39-2.00)	0.82 (0.36-1.90)
Migraine headache - 1.14 (0.48–2.68) 1.17 (0.49–2.81) Sleep disorder diagnosis - 0.67 (0.20–2.18) 0.72 (0.22–2.38) Clinical care - - - - Prescribed benzodiazepine in the year prior to discontinuation - - 0.68 (0.26–1.81) Average MEDD in the year prior to discontinuation - - 0.60 (1.00–1.01) Reason for discontinuation of opioid therapy - - - Aberrant behaviors - - - Patient safety concerns - - -	Neuropathic pain	-	0.99 (0.27-3.69)	0.93 (0.24-3.61)
Sleep disorder diagnosis-0.67 (0.20–2.18)0.72 (0.22–2.38)Clinical care0.68 (0.26–1.81)Prescribed benzodiazepine in the year prior to discontinuation0.68 (0.26–1.81)Average MEDD in the year prior to discontinuation1.00 (1.00–1.01)Reason for discontinuation of opioid therapyAberrant behaviors1.61 (0.76–3.42)Patient safety concerns2.06 (0.82–5.18)	Migraine headache	-	1.14 (0.48-2.68)	1.17 (0.49–2.81)
Clinical care-0.68 (0.26-1.81)Prescribed benzodiazepine in the year prior to discontinuation0.68 (0.26-1.81)Average MEDD in the year prior to discontinuation1.00 (1.00-1.01)Reason for discontinuation of opioid therapyAberrant behaviors1.61 (0.76-3.42)Patient safety concerns2.06 (0.82-5.18)	Sleep disorder diagnosis	-	0.67 (0.20–2.18)	0.72 (0.22-2.38)
Prescribed benzodiazepine in the year prior to discontinuation0.68 (0.26-1.81)Average MEDD in the year prior to discontinuation1.00 (1.00-1.01)Reason for discontinuation of opioid therapyAberrant behaviors1.61 (0.76-3.42)Patient safety concerns2.06 (0.82-5.18)	Clinical care			
Average MEDD in the year prior to discontinuation1.00 (1.00-1.01)Reason for discontinuation of opioid therapy1.61 (0.76-3.42)Aberrant behaviors2.06 (0.82-5.18)Patient safety concerns2.06 (0.82-5.18)	Prescribed benzodiazepine in the year prior to discontinuation	-	-	0.68 (0.26-1.81)
Reason for discontinuation of opioid therapy1.61 (0.76–3.42)Aberrant behaviors2.06 (0.82–5.18)Patient safety concerns2.06 (0.82–5.18)	Average MEDD in the year prior to discontinuation	-	-	1.00 (1.00-1.01)
Aberrant behaviors - - 1.61 (0.76–3.42) Patient safety concerns - - 2.06 (0.82–5.18)	Reason for discontinuation of opioid therapy			
Patient safety concerns - - 2.06 (0.82–5.18)	Aberrant behaviors	-	-	1.61 (0.76-3.42)
	Patient safety concerns	-	-	2.06 (0.82-5.18)

Results presented as adjusted odds ratios (95% confidence intervals). The analytic sample comprised 59 patients with SI/SSV and 450 patients without SI/SSV in the year following discontinuation of opioid therapy.

Demographic characteristics, clinical diagnoses, medical comorbidities, and prescription information were obtained for the year prior to discontinuation of opioid therapy. Substance use disorder diagnosis category includes alcohol use disorder diagnoses and excludes tobacco use disorder diagnoses.

MEDD = Morphine Equivalent Daily Dose; PTSD = Post-traumatic Stress Disorder; SI = Suicidal Ideation, SSV = Non-fatal Suicidal Self-directed Violence, VHA = Veterans Health Administration.

* p < 0.05.

3.1. Correlates of SI/SSV following clinician-initiated discontinuation of opioid therapy

Younger age (OR = 0.97 [95% CI = 0.95-1.00]) and self-identifying as Hispanic ethnicity (OR = 6.48 [1.88-22.35]) were associated with an increased likelihood of SI/SSV in the year following discontinuation of opioid therapy (see Table 2, Model 1). However, only Hispanic ethnicity remained a significant demographic correlate of SI/ SSV in the fully adjusted model (Model 3). Having a PTSD diagnosis (OR = 2.33 [1.14-4.78]) or psychotic-spectrum disorder diagnosis (OR = 3.34 [1.23-9.11]) in the year prior to opioid discontinuation was also significantly associated with SI/SSV at model entry (see Table 2, Model 2) and these associations remained significant in the fully adjusted model. Although opioid discontinuation due to patient safety concerns was associated with an increased likelihood of having SI/SSV in bivariate analyses (see Table 1), it was unrelated to SI/SSV in the covariate-adjusted model (OR = 2.06 [0.82-5.18]). Table 2 provides effect size estimates as measured by the odds ratio for each variable at model entry and in the final, fully adjusted model.

3.2. Correlates of new onset SI/SSV

Multivariate analyses were conducted for the reduced sample of n = 484 patients (34 with new onset SI/SSV and 450 without SI/SSV in the year following discontinuation of opioid therapy). Results were generally unchanged from those for the full sample described above. In the fully adjusted model, only Hispanic ethnicity, PTSD diagnosis, and psychotic disorder diagnosis were significantly related to SI/SSV (see

Table 3 for effect size estimates for each variable at model entry and in the final, fully adjusted model). The one exception was that age was unrelated to SI/SSV in the reduced sample at model entry (see Table 3, Model 1).

4. Discussion

In this national sample of VHA patients with substance use disorder diagnoses and similar matched patients who were discontinued from long-term opioid therapy by their opioid-prescribing clinicians, nearly 12% had documentation in the medical record of SI/SSV in the year following discontinuation-9.2% with SI only and 2.4% with SSV. This is higher than the 12-month incidence of self-reported suicidal ideation (3.8%) and attempts (0.4%) found in a community sample of veterans in two U.S. states surveyed through the Behavioral Risk Factor Surveillance System Veteran's Health Module [20], while lower than the self-reported SI incidence of 24% and commensurate with the SSV incidence of 2% in the past 12 months for VHA patients referred to primary care mental health services [21]. That rates of SSV in the current study were most commensurate with a sample of mental health treatment-seeking veteran patients may be due to the selection of patients with substance use disorders and similar matched patients, given high rates of comorbidity between substance use and mental health disorders. Indeed, 61% of patients in the current study had one or more mental health disorder diagnoses documented in the medical record in the year prior to opioid discontinuation. However, unlike prior studies that obtained patient self-reported SI and SSV, our estimates of SI and SSV were ascertained from medical record

Table 3

Multivariate correlates of new onset suicidal ideation or non-fatal suicidal self-directed violence in the year following discontinuation of long-term opioid therapy.

	Model 1	Model 2	Model 3
Demographic characteristics			
Age	0.98 (0.95-1.01)	0.98 (0.94-1.01)	0.97 (0.94-1.01)
Male gender	1.07 (0.23-4.93)	0.83 (0.17-4.03)	0.72 (0.15-3.57)
Race			
White, non-Hispanic	Reference	Reference	Reference
Black, non-Hispanic	1.18 (0.46-3.02)	1.19 (0.44–3.21)	1.15 (0.42-3.15)
Hispanic	10.69 (2.76-41.34)*	17.69 (4.03-77.61)*	16.49 (3.71-73.35)*
Other/unknown	0.96 (0.27–3.35)	1.14 (0.31–4.13)	1.06 (0.28-3.93)
Clinical diagnoses and medical comorbidities			
Elixhauser Medical Comorbidity Score	-	0.67 (0.44-1.03)	0.70 (0.46-1.07)
Any VHA Service Connected Disability	-	0.55 (0.24-1.28)	0.56 (0.24-1.31)
Mental health diagnoses			
Depressive disorder	-	0.91 (0.37-2.24)	0.93 (0.38-2.31)
Bipolar disorder	-	0.30 (0.04–2.43)	0.28 (0.03-2.37)
PTSD	-	3.61 (1.37-9.55)*	3.78 (1.41-10.14)*
Other anxiety disorders	-	1.09 (0.44–2.65)	1.06 (0.43-2.60)
Psychotic-spectrum disorders	-	6.51 (1.71-24.75)*	6.72 (1.73-26.17)*
Substance use disorder diagnosis	-	0.92 (0.43-2.00)	0.86 (0.39-1.87)
Tobacco use disorder diagnosis	-	0.82 (0.37-1.79)	0.74 (0.33-1.67)
Chronic pain diagnoses			
Muskuloskeletal pain	-	1.24 (0.42–3.70)	1.24 (0.41-3.75)
Neuropathic pain	-	0.87 (0.11-7.00)	1.09 (0.13-9.06)
Migraine headache	-	0.52 (0.13-2.04)	0.49 (0.12-1.96)
Sleep disorder diagnosis	-	1.05 (0.26-4.24)	1.14 (0.28-4.60)
Clinical care			
Prescribed benzodiazepine in the year prior to discontinuation	-	-	0.73 (0.21-2.59)
Average MEDD in the year prior to discontinuation	-	-	1.00 (1.00-1.01)
Reason for discontinuation of opioid therapy			
Aberrant behaviors	-	-	1.89 (0.70-5.13)
Patient safety concerns	-	-	0.89 (0.18–4.44)

Results presented as adjusted odds ratios (95% confidence intervals). The analytic sample comprised 34 patients with new onset SI/SSV and 450 patients without SI/SSV in the year following discontinuation of opioid therapy.

Demographic characteristics, clinical diagnoses, medical comorbidities, and prescription information were obtained for the year prior to discontinuation of opioid therapy. Substance use disorder diagnosis category includes alcohol use disorder diagnoses and excludes tobacco use disorder diagnoses.

MEDD = Morphine Equivalent Daily Dose; PTSD = Post-traumatic Stress Disorder; SI = Suicidal Ideation, SSV = Non-fatal Suicidal Self-directed Violence, VHA = Veterans Health Administration.

* p < 0.05.

documentation only. It is likely that we underestimated the actual proportion of patients who experienced SI or SSV in the year following discontinuation of opioid therapy. Within VHA, patients receiving mental health services are routinely asked about current suicidal ideation. Our findings suggest that asking these questions of patients who discontinue long-term opioid therapy may help identify patients in this population with SI, at which point intervening actions and safety planning can occur before patients engage in self-harm behaviors [22].

To our knowledge, ours is the first study to examine correlates of SI and SSV subsequent to discontinuation of long-term opioid therapy in patients with chronic pain. A prior study examined correlates of SI and SSV in a sample of patients with chronic pain prescribed opioid therapy for at least six weeks [23]. The strongest predictors of past 12 months reported SI was a diagnosis of depression and a lifetime suicide attempt. Pain-related factors, such as specific pain diagnoses, severity of pain, and physical functioning were unrelated to SI. The authors concluded that patient samples comprising people prescribed opioid therapy for chronic pain may represent those whose pain is more severe, and pain-related variables thus have less of an association with SI/SSV [23]. Findings from our study corroborate the finding that mental health diagnoses (PTSD and psychotic disorders in our sample) are more strongly associated with SI/SSV than pain-related factors and extend this finding to patients who discontinue opioid therapy.

Substance use disorder diagnoses in general were unrelated to SI/ SSV in the current study. Among veterans, substance use disorder diagnoses have been shown to be unrelated to suicide outcomes after controlling for mental health variables [16]. One possible explanation of this finding is that while substance use can lead to behavioral impulsivity and disinhibition, it must be paired with acute negative mood to elicit suicidal thoughts and self-directed violent behaviors [24]. Substance use in the absence of negative mood states may be insufficient to precipitate these suicidal thoughts and behaviors. An exception in the current study was the finding that a diagnosis of sedative use disorder was associated with SI/SSV in bivariate analyses, suggesting that some specific substance use disorders may be more strongly associated with SI/SSV than others. However, having a benzodiazepine prescription was unrelated to SI/SSV. It is notable that we identified six patients with documented suicide attempts via drug overdose and four of these attempts involved benzodiazepines. These data suggest that benzodiazepines by themselves may not be related to suicidality unless benzodiazepine misuse is present, as is the case for patients with sedative use disorders. In addition to monitoring patients for SI subsequent to opioid discontinuation, it may be particularly important for clinicians to pay close attention to patients with sedative use disorders who may have access to potentially lethal doses of their "drug of choice" in benzodiazepines, even when not prescribed these medications.

An unexpected finding was the association between Hispanic ethnicity, relative to non-Hispanic whites, and SI/SSV. This finding contradicts the preponderance of evidence synthesized in systematic reviews that has found Hispanic ethnicity to be unrelated to SI [16,25]. In our study, point estimates for the likelihood of having SI/SSV for Hispanic patients are bracketed by wide confidence intervals, likely due to the small number of Hispanic patients in this sample—only 11 patients (2.2%) out of 509 self-identified with Hispanic ethnicity, and nearly half of these patients (5 of 11) had some form of SI documented

Hispanic population [25].

4.1. Limitations

in the medical record in the 12 months following discontinuation of opioid therapy. Additional research is needed to further explore the relationship between Hispanic ethnicity and SI following discontinuation of long-term opioid therapy. Particular attention should be given to Research and Development Center to Improve Veteran Involvement in Care (CIVIC; CIN 13-404, PI: Dobscha) at the VA Portland Health Care System for the provision of support and resources for this project.

References

- Deyo RA, Von Korff M, Duhrkoop D. Opioids for low back pain. BMJ 2015;350:g6380.
- [2] Edlund MJ, Austen MA, Sullivan MD, Martin BC, Williams JS, Fortney JC, et al. Patterns of opioid use for chronic noncancer pain in the Veterans Health Administration from 2009 to 2011. Pain 2014;155:2337–43.
- [3] Daubresse M, Chang HY, Yu Y, Viswanathan S, Shah ND, Stafford RS, et al. Ambulatory diagnosis and treatment of nonmalignant pain the United States. Med Care 2000–2010;2013:870–8.
- [4] Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. MMWR Recomm Rep 2016;65:1–49.
- [5] Lin LA, Bohnert ASB, Kerns RD, Clay MA, Ganoczy D, Ilgen MA. Impact of the opioid safety initiative on prescribing in veterans. Pain 2017;158:833–9.
- [6] Lovejoy TI, Morasco BJ, Demidenko MI, Meath THA, Frank JW, Dobscha SK. Reasons for discontinuation of long-term opioid therapy in patients with and without substance use disorders. Pain 2017;158:526–34. http://dx.doi.org/10. 1097/j.pain.000000000000796.
- [7] Webster LR. Is suicide a consequence of the CDC opioid guideline? Pain medicine news. 11 August 2016; 11 August 2016 Available from: http://www. painmedicinenews.com/Commentary/Article/08-16/Is-Suicide-a-Consequence-ofthe-CDC-Opioid-Guideline-/37442/ses = ogst (accessed September 21, 2016).
- [8] Webster LR. Pain and suicide: the other side of the opioid story. Pain Med 2014;15:345–6.
- [9] Ilgen MA, Bohnert ASB, Ganoczy D, Bair MJ, McCarthy JF, Blow FC. Opioid dose and risk of suicide. Pain 2016;157:1079–84.
- [10] Fishbain DA, Lewis JE, Gao J. The pain-suffering association, a review. Pain Med 2015;16:1057–72.
- [11] Manchikanti L, Helm S, Fellows B, Janata JW, Pampati V, Grider JS, et al. Opioid epidemic in the United States. Pain Physician 2012;15:ES9–38.
- [12] VA/DoD. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. Washington, DC: Veterans Administration; 2010 Available from: http://www.va.gov/painmanagement/docs/cpg_opioidtherapy_fulltext.pdf.
- [13] Crosby AE, Ortega L, Melanson C. Self-directed violence surveillance: uniform definitions and recommended data elements, version 1.0. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control: Atlanta (GA); 2011.
- [14] Morasco BJ, Turk DC, Donovan DM, Dobscha SK. Risk for prescription opioid misuse among patients with a history of substance use disorder. Drug Alcohol Depend 2013;127:193–9.
- [15] Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8–27.
- [16] Dobscha SK, Denneson LM, Kovas AE, Teo A, Forsberg CW, Kaplan MS, et al. Correlates of suicide among veterans treated in primary care: case-control study of a nationally representative sample. J Gen Intern Med 2014;29:S853–60.
- [17] Haney EM, O'Neil ME, Carson S, Low A, Peterson K, Denneson LM, et al. Suicide risk factors and risk assessment tools: a systematic review. VA evidence-based synthesis program reports. Washington, DC: Department of Veterans Affairs; 2012.
- [18] Tang NKY, Crane C. Suicidality in chronic pain: a review of the prevalence, risk factors and psychological links. Psychol Med 2006;36:576–86.
- [19] Morrill R, Cromartie J, Hart LG. Metropolitan, urban, and rural commuting areas: toward a better depiction of the U.S. settlement system. Urban Geogr 1999;20:727–48.
- [20] Bossarte RM, Knox KL, Piegari R, Altieri J, Kemp J, Katz IR. Prevalence and characteristics of suicide ideation and attempts among active military and veteran participants in a national health survey. Am J Public Health 2012;102:S38–40.
- [21] Ashrafioun L, Pigeon WR, Conner KR, Leong SH, Oslin DW. Prevalence and correlates of suicidal ideation and suicide attempts among veterans in primary care referred for a mental health evaluation. J Affect Disord 2016;189:344–50.
- [22] Ganzini L, Denneson LM, Press N, Bair MJ, Helmer DA, Poat J, et al. Trust is the basis for effective suicide risk screening and assessment in veterans. J Gen Intern Med 2013;28:1215–21. http://dx.doi.org/10.1007/s11606-013-2412-6.
- [23] Campbell G, Bruno R, Darke S, Shand F, Hall W, Farrell M, et al. Prevalence and correlates of suicidal thoughts and suicide attempts in people prescribed pharmaceutical opioids for chronic pain. Clin J Pain 2016;32:292–301.
- [24] Pompili M, Serafini G, Innamorati M, Dominici G, Ferracuti F, Kotzalidis GD, et al. Suicidal behavior and alcohol abuse. Int J Environ Res Public Health 2010;7:1392–431.
- [25] Perez-Rodriguez MM, Baca-Garcia E, Oquendo MA, Blanco C. Ethnic differences in suicidal ideation and attempts. Prim Psychiatry 2008;15:44–53.

4.2. Conclusions

SSV in this population.

A substantial proportion of patients with substance use disorder diagnoses and similar matched patients experience SI or SSV following discontinuation of long-term opioid therapy by opioid-prescribing clinicians, most of whom represent new onset cases. As in the general suicide and chronic pain-specific literature, mental health diagnoses appear to be more strongly correlated with SI and SSV relative to painspecific factors. Primary care clinicians and allied mental health providers should pay extra attention to safety when patients are discontinued from long-term opioid therapy, particularly patients with PTSD or psychotic disorders.

identifying Hispanic ethnicity subgroups (e.g., Puerto Rican, Cuban,

Mexican) and levels of acculturation, as these factors may account for differences in prevalence of mental health disorders and SI within the

Findings from this study should be considered in light of its

limitations. First, the study sample comprised VHA patients with

substance use disorder diagnoses in the year prior to discontinuation

of opioid therapy and a matched sample without substance use disorder

diagnoses. Results may not generalize to the general population of VHA

or non-VHA patients. Second, we excluded patients who died in the

year following discontinuation of opioid therapy. Our sample may thus

underestimate the proportion of patients that experience SI/SSV

following opioid discontinuation, as those who died by suicide in the

year following discontinuation of opioid therapy would have been

excluded. Third, we did not review pre-discontinuation chart notes for

the presence SI/SSV for the 450 patients with no SI/SSV documented

post-discontinuation. As a result, we were unable to determine baseline

rates of SI/SSV in this sample prior to discontinuation of opioid

therapy. Fourth, sample size limitations precluded an examination of

demographic, medical comorbidity, and other clinical variables asso-

ciated with SSV alone. Finally, SI/SSV was ascertained based solely on

medical chart review, which likely underestimates actual rates of SI/

Disclaimer

The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the U.S. Department of Veterans Affairs or U.S. Government.

Acknowledgments

This work was supported by Locally Initiated Project Award # QLP 59-048 (PI: Lovejoy) from the United States (U.S.) Department of Veterans Affairs Substance Use Disorder Quality Enhancement Research Initiative. Dr. Lovejoy received additional support from Career Development Award IK2HX001516 from the U.S. Department of Veterans Affairs Health Services Research and Development during preparation of this manuscript. We thank the VA Portland Health Care System and the U.S. Department of Veterans Affairs Health Services